ノルエピネフリン輸送体の形状選択的調節を明らかにする
Heng Zhang1, Tianwei Zhang2, Dingyan Wang3
1The State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Cell
|October 25, 2025
まとめ
研究者らは,うつ病とADHDの治療に不可欠なノレピネフリントランスポーター (NET) の新しいアロステリック部位を発見しました. この発見は,NETをターゲットとする薬の開発のための"バルブモデル"を明らかにしています.
科学分野:
- 神経科学
- 薬理学について
- 構造生物学
背景:
- ノルエピネフリントランスポーター (NET) はシナプス神経伝達に不可欠です.
- NET機能障害は重度のうつ病と注意欠陥/多動性障害 (ADHD) と関連しています.
- NETのアロステリック調節を理解することは,標的治療の開発の鍵です.
研究 の 目的:
- NETのアロステリック・コンフォーム・セレクティブ・レギュレーションを解明する.
- 新しいアロステリック部位とNETの規制メカニズムを特定する.
- 次世代のNET阻害剤の開発のための構造主導の枠組みを提供すること.
主な方法:
- 抑制剤 (レボミルナシプラン,バノキセリン,ビラゾドン) を含むNET複合体の冷凍電子顕微鏡検査
- アロステル結合部位を特定するための構造分析
- 新しいNET阻害剤を発見するための仮想スクリーニング
- 特定された抑制剤のインビトロおよびインビボの検証
主要な成果:
- NETの内側前庭に以前未定義のアロステリック部位が特定されました.
- 構成選択的阻害剤結合を説明する"バルブモデル"が提案された.
- 強力なNET阻害活性を持つ新しい阻害剤が発見されました.
- 臨床前モデルで特定された抑制剤の抗うつ効果が実証された.
結論:
- 特定されたアロステリックサイトと"バルブモデル"は,NETの規制のためのメカニズム的枠組みを提供します.
- 構造に基づく洞察は神経精神疾患の標的治療法の開発を容易にする.
- この研究は,次世代の抗うつ薬の設計のためのNETアロステリック調節の理解を進める.
関連する概念動画
Drugs Affecting Neurotransmitter Release or Uptake
1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
Adrenergic Neurons: Neurotransmission
5.1K
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
Synthesis: Catecholamine synthesis requires tyrosine, which...
5.1K
Adrenergic Receptors: β Subtype
3.5K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.5K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K
Adrenergic Receptors: ɑ Subtype
2.7K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.7K
Adrenergic Receptors (Adrenoceptors): Classification
4.6K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
4.6K


